



SUVN-G3031

Histamine H₃ Inverse Agonist

Cognitive Disorders (Alzheimer's)

Sleep Disorders (Narcolepsy)

Phase 1 Completed in USA;

Phase-2 for Narcolepsy; Planned for Q3 / Q4 2018



SUVN-G3031: Differentiated Pharmacology for AD and Narcolepsy




- Potent and selective histamine H₃ receptor inverse agonist
- Good brain penetration with adequate free CSF concentrations
- Robust efficacy in animal models; increases acetylcholine, norepinephrine and histamine levels
- Potentiates the efficacy of standard of care in animal models
- EEG activity with good separation between doses for cognition and sleep disorders
- Translatable biomarker available for POC study
- Good cardiovascular safety profile
- Excellent margin of safety in all long term toxicity studies
- No genotoxicity and teratogenic potential
- Well protected intellectual property in all major countries
- Safe and well tolerated in healthy subjects
- Favorable pharmacokinetics for once a day dosing
- No sleep disturbances up to doses several fold higher than the projected therapeutic dose range for cognition disorders
- Projected human efficacy concentrations achieved in Phase 1 study
- No effect of food, gender and age on human pharmacokinetics


SUVN-G3031: Key Pharmacology Results




Target Engagement



Efficacy Pharmacology



Sleep/wake Profile



Potential for therapeutic use in

- cognitive deficits
- sleep disorders

SUVN-G3031: Clinical Studies Summary and Current Status



- Well tolerated in humans with dose dependent pharmacokinetics
- Suitable for once a day oral dosing
- Projected human efficacy concentrations achieved at low doses in Phase 1 study

Current status: Phase 1 completed in USA

Phase-2 for Narcolepsy; Planned for Q3 / Q4 2018



Contacts:

Venkat Jasti

Chairman & CEO

E-mail: jasti@suven.com

Ramakrishna Nirogi

Vice President, Discovery Research

E-mail: nvsrk@suven.com